| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: | | | | | | | | |
| Grants and contracts | 1.5 | | 1.1 | 1.1 | 1.9 | 3.5 | 2.7 | 3.7 |
| Grants and contracts growth | | -100.0% | -2.2% | -41.6% | -44.6% | 29.9% | -26.8% | -56.4% |
| Cost of goods sold | 0.5 | | | | | | | |
| Gross profit | 1.0 | | | | | | | |
| Gross margin | 67.2% | | | | | | | |
| |
| Operating expenses: | | | | | | | | |
| Research and development | 11.8 | 5.3 | 1.7 | 3.6 | 5.0 | 6.5 | 7.1 | 9.7 |
| Sales and marketing expense | 0.1 | 0.0 | | | | | | |
| General and administrative | 19.8 | 5.2 | 1.8 | 2.3 | 2.5 | 3.4 | 6.4 | 8.5 |
| Total operating expenses | 99.3 | 10.5 | 3.5 | 5.9 | 7.5 | 19.8 | 13.5 | 18.1 |
| Loss from operations | -98.3 | -10.5 | -2.4 | -4.8 | -5.6 | -6.4 | -10.8 | -14.4 |
| Operating margin | -6613.4% | | -212.0% | -421.7% | -287.5% | -180.6% | -398.5% | -389.6% |
| |
| Other expense: | | | | | | | | |
| Interest and other expense | -4.6 | -1.1 | -0.4 | 0.1 | 0.2 | 0.3 | -0.1 | -1.1 |
| Total other expense | -8.1 | -1.6 | -0.7 | 1.1 | -4.2 | 3.8 | -2.3 | 14.5 |
| Income from discontinued operations, net of income taxes | 0.0 | | | | | | | |
| Net loss | -101.9 | -12.1 | -2.7 | -3.7 | -9.8 | -2.6 | -13.0 | 0.0 |
| Net loss attributable to noncontrolling interests | 0.0 | | 0.0 | 0.1 | 0.1 | 0.1 | -0.4 | -1.6 |
| Net loss attributable to Statera Biopharma, Inc. | -101.9 | -12.1 | -2.6 | -3.6 | -9.8 | -2.6 | -13.0 | 0.0 |
| |
| Net loss attributable to common stockholders per share of common stock, basic and diluted | ($2.90) | ($1.66) | ($0.23) | ($0.32) | ($0.87) | ($0.24) | ($1.79) | $0.60 |
| |
| Weighted average number of shares used in calculating net loss per share, basic and diluted | 35.1 | 7.3 | 11.3 | 11.3 | 11.2 | 11.0 | 7.1 | 2.7 |